Last reviewed · How we verify

Placebe of HS-25 and Atorvastatin

Zhejiang Hisun Pharmaceutical Co. Ltd. · Phase 3 active Small molecule

Placebe of HS-25 and Atorvastatin is a statin Small molecule drug developed by Zhejiang Hisun Pharmaceutical Co. Ltd.. It is currently in Phase 3 development for Hypercholesterolemia, Hyperlipidemia.

Atorvastatin is a statin that inhibits HMG-CoA reductase to lower cholesterol levels.

Atorvastatin is a statin that inhibits HMG-CoA reductase to lower cholesterol levels. Used for Hypercholesterolemia, Hyperlipidemia.

At a glance

Generic namePlacebe of HS-25 and Atorvastatin
SponsorZhejiang Hisun Pharmaceutical Co. Ltd.
Drug classstatin
TargetHMG-CoA reductase
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

By inhibiting HMG-CoA reductase, atorvastatin reduces the liver's production of cholesterol, which in turn lowers the levels of low-density lipoprotein (LDL) cholesterol in the blood. This is beneficial for patients with high cholesterol, as elevated LDL levels are a major risk factor for cardiovascular disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebe of HS-25 and Atorvastatin

What is Placebe of HS-25 and Atorvastatin?

Placebe of HS-25 and Atorvastatin is a statin drug developed by Zhejiang Hisun Pharmaceutical Co. Ltd., indicated for Hypercholesterolemia, Hyperlipidemia.

How does Placebe of HS-25 and Atorvastatin work?

Atorvastatin is a statin that inhibits HMG-CoA reductase to lower cholesterol levels.

What is Placebe of HS-25 and Atorvastatin used for?

Placebe of HS-25 and Atorvastatin is indicated for Hypercholesterolemia, Hyperlipidemia.

Who makes Placebe of HS-25 and Atorvastatin?

Placebe of HS-25 and Atorvastatin is developed by Zhejiang Hisun Pharmaceutical Co. Ltd. (see full Zhejiang Hisun Pharmaceutical Co. Ltd. pipeline at /company/zhejiang-hisun-pharmaceutical-co-ltd).

What drug class is Placebe of HS-25 and Atorvastatin in?

Placebe of HS-25 and Atorvastatin belongs to the statin class. See all statin drugs at /class/statin.

What development phase is Placebe of HS-25 and Atorvastatin in?

Placebe of HS-25 and Atorvastatin is in Phase 3.

What are the side effects of Placebe of HS-25 and Atorvastatin?

Common side effects of Placebe of HS-25 and Atorvastatin include Muscle pain, Liver enzyme elevation, Diarrhea.

What does Placebe of HS-25 and Atorvastatin target?

Placebe of HS-25 and Atorvastatin targets HMG-CoA reductase and is a statin.

Related